Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01886404 · ClinicalTrials.gov registry record
EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 30
- Enrollment target
NCT01886404: Completed study, sponsored by University of Nebraska.
NCT01886404 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01886404 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The primary purpose of this study is to investigate the steady-state pharmacokinetics of efavirenz in older HIV-infected patients as compared to historical controls; to investigate the relationship of drug exposure to neuropsychiatric side effects and neuropsychological performance; and to explore the role of host polymorphisms in drug metabolism in the older patient.
Primary Outcome
plasma concentrations of efavirenz in older HIV-infected patients measured by Liquid Chromatography Mass Spectrometry (LC-MS-MS).
Interventions
- DRUG Efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-12-01 |
| Est. Completion | 2014-08-01 |
What the finished NCT01886404 record still lists
NCT01886404 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Efavirenz is the first listed.
NCT01886404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01886404 about?
NCT01886404 is a clinical study titled "EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients". The primary purpose of this study is to investigate the steady-state pharmacokinetics of efavirenz in older HIV-infected patients as compared to historical controls; to investigate the relationship of drug exposure to neuropsychiatric side effects and neuropsychological performance; and to explore t...
What is the current status of trial NCT01886404?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-12-01. Estimated completion is 2014-08-01.
What interventions are being tested in trial NCT01886404?
The interventions under investigation include: Efavirenz (DRUG).
Who is sponsoring clinical trial NCT01886404?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI